Ramosetron
Structural formula | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
![]() |
||||||||||||||||
General | ||||||||||||||||
Non-proprietary name | Ramosetron | |||||||||||||||
other names |
(1-Methyl-1 H -indol-3-yl) [(5 R ) -4,5,6,7-tetrahydro-1 H -benzimidazol-5-yl] methanone ( IUPAC ) |
|||||||||||||||
Molecular formula | C 17 H 17 N 3 O | |||||||||||||||
External identifiers / databases | ||||||||||||||||
|
||||||||||||||||
Drug information | ||||||||||||||||
Drug class | ||||||||||||||||
properties | ||||||||||||||||
Molar mass | 279.33 g · mol -1 | |||||||||||||||
safety instructions | ||||||||||||||||
|
||||||||||||||||
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . |
Ramosetron is a serotonin - 5-HT3 - antagonists for the treatment of nausea and vomiting during chemotherapy and after surgery ( PONV ). Ramosetron has a higher affinity for the 5-HT receptor than ondansetron , granisetron and tropisetron . Ramosetron is also used to treat irritable bowel syndrome .
Ramosetron is currently only available in Japan, certain countries in Southeast Asia and India. In Japan, it is sold under the trade name Irribow (イ リ ボ ー) as a tablet (2.5 or 5 micrograms per tablet, treatment of irritable bowel syndrome). In India it is sold under the name Nozia (treatment of nausea and vomiting) and IBSet (for the treatment of diarrhea in the case of irritable bowel syndrome) and in the rest of the world under the name Nasea , common strengths are 300 micrograms / 2 ml solution for injection and 100 respectively Micrograms per tablet.
Individual evidence
- ↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
- ↑ Izumi Tooru et al: Antiemetic effects of ramosetron hydrochloride during chemotherapy for hematological malignancies . In: Hematology & Oncology . tape 45 , no. 1 , 2002, p. 89–92 ( abstract ( memento from February 18, 2013 in the web archive archive.today )). Antiemetic effects of ramosetron hydrochloride during chemotherapy for hematological malignancies ( Memento from February 18, 2013 in the web archive archive.today )
- ↑ JH Ryu, HM Sohn, SJ Park, SH Do: Ramosetron vs. ramosetron plus dexamethasone on the PONV after la * paroscopic cholecystectomy: 1AP4-2 . In: European Journal of Anaesthesiology (EJA) . tape 29 , 2012, p. 13 ( full text ).
- ^ X. Rabasseda: Ramosetron, a 5-HT3 receptor antagonist for the control of nausea and vomiting . In: Drugs of Today . tape 38 , no. 2 , February 2002, p. 75–89 , doi : 10.1358 / dot.2002.38.2.820104 .
- ^ Astellas Pharma Inc .: Astellas Launches Irribow® for the Treatment of Irritable Bowel Syndrome ( Memento from February 27, 2012 in the Internet Archive ), press release from October 6, 2008.
- ↑ イ リ ボ ー 錠 5μg (ア ス テ ラ ス 製 薬 株式会社) の 効果 と 副作用 、 使用 上 の 注意) = Effects and side effects of Irribow tablets (5 µg, Astellas Pharma, Inc.). QLife, accessed January 8, 2013 (Japanese).